Trial
NCT04016116
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
—
Condition
Cancer
Intervention
Pembrolizumab
Why stopped
PI left the institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-27